Here are three things to know.
1. This brings Fidelity’s holdings in Cynata to about 10 percent.
2. Fidelity will get 4 million shares at $1.28 each, a 4.5 percent premium to Cynata’s closing price May 25.
3. Cynata’s proprietary Cymerus stem cell platform technology enables the company to manufacture mesenchymal stem cells on a commercial scale.
More articles on biologics:
The global spine biologics market to grow at CAGR of 4.1% through 2022: 3 things to know
DiscGenics treats 1st patient in degenerative disc disease clinical trial: 5 things to know
